This paper reports the anti-cryptosporidial effects of, and concomitant amelioration of the histological changes in the gut of neonatal rats with intestinal cryptosporidiosis treated with the dinitroaniline, oryzalin. The ED &! was determined to be 7 mg\kg using twice daily doses administered for 3 consecutive days. A maximum inhibition of 85n5 % was achieved at 25 mg\kg and this inhibition remained constant despite increasing the oryzalin dose to 200 mg\kg. Cryptosporidiosis significantly decreased the intestinal villus\crypt (VC) ratio by approximately 50 % (duodenum l 2n3, jejunum l 2n5 and ileum l 1n7) when compared to uninfected untreated controls (duodenum l 4n3, jejunum l 5n9 and ileum l 4n5). Treatment with oryzalin doubled the VC ratio in the duodenum, jejunum and ileum following doses of 5 mg, 50 mg and 200 mg\kg respectively. Oryzalin concentrations in the small intestine contents and plasma were determined, using HPLC, at 0n5, 1 and 2 h after dosing. The much greater dose required to return VC ratios to normal in the ileum (200 mg\kg) compared to the duodenum (6n25 mg\kg) appeared to reflect the decreased concentration of the drug in the distal small intestine. Concentrations of oryzalin equivalent to the in vitro IC &! were maintained for 2 h in the first half of the small intestine following a single dose of 100 mg\kg.

An effective anti-cryptosporidial agent is yet to be found despite the fact that over 200 compounds have been examined (Woods et al. 1996 ; Armson et al. 1999 a) . In the absence of a treatment that is completely efficacious against C. parvum, a drug that decreases oocyst numbers and thus parasite proliferation in the gut, concurrently minimizing the symptoms of this disease must suffice. We have recently demonstrated the activity of the dinitroaniline oryzalin in vivo against C. parvum using both a mouse and a rat model and showed that oryzalin achieved a 90 % inhibition of oocyst numbers using twice daily doses of 25 mg\kg oryzalin administered over 3 consecutive days (Armson et al. 1999 b) .
While there is extensive literature on the in vitro anti-cryptosporidial effects of the dinitroanilines (Arrowood et al. 1996 ; Benbow et al. 1998 ; Callahan et al. 1996) there is very little information on the in vivo effects of this class of compounds (Armson et al. 1999 b) . This paper follows our previous work on the in vitro and in vivo effects of the dinitroanilines and reports on the effects of a range of doses of oryzalin in infected animals, with respect to anti-parasite efficacy, histological changes and pharmacokinetics.
The observation that a diminished villus crypt (VC) ratio is most severe and more noticeable in the acute phase of parasitosis enables an assessment of the relative severity of the disease (Roberts- Thompson et al. 1976 ). This can be done by determining the VC ratio in uninfected, infected untreated and infected treated animals receiving different doses of the treatment. The aims of this study were firstly to determine the dose-response relationship for oryzalin in the treatment of murine cryptosporidiosis, secondly to use the VC ratio to examine the relationship between gastrointestinal damage caused by cryptosporidial infection and oryzalin dosage in infected animals, and lastly to examine the pharmacokinetics of the drug in neonatal rats. The resultant information will provide an insight into the efficacy of this drug against C. parvum.
  

Isolation of infective Cryptosporidium oocysts
A bovine Cryptosporidium isolate was collected from calf faecal samples using phosphate-buffered saline (PBS)-ether sedimentation and washing as described by Morgan, Reynoldson & Thompson (1993) . inoculated into forty 7-to 8-day-old SpragueDawley rats via gastric intubation at a dose rate of 10-12i10% oocysts per animal, using the method of Meloni & Thompson (1996) . Stock solutions of drugs were made in 5 ml aliquots. Drugs were dissolved in 0n5 ml of dimethyl sulfoxide (Me # SO) which was then added to 4n5 ml peanut oil using a modification of the method described by Fayer & Fetterer (1995) . On day 4 post-infection, the animals were weighed and the mean weight for each litter calculated, allowing for between-litter variation. Using random numbers 36 rats were randomly divided into 9 groups of 4 rats. Using the mean weight, the oryzalin dose rate was determined such that each group of 4 rats received either 200, 100, 50, 25, 12n5, 6n25 or 3n125 mg\kg of drug in 100 µl vehicle per rat twice daily for 3 consecutive days. The remaining 2 groups of 4 rats were controls including infected untreated and uninfected animals with both groups receiving drug vehicle alone. All rats were sacrificed on day 7 post-infection and processed in the manner described above (Morgan et al. 1993) . Samples were collected into 10 % formaldehyde from the proximal duodenum, midjejunum, terminal ileum, distal caecum and terminal colon. Routine haematoxylin and eosin-stained sections were used to evaluate the pathological changes and measure VC ratios. Remaining gut contents were processed individually and oocyst load determined separately. Oocyst production for each animal was determined by counting the oocysts from the processed gut following separation using a Ficoll gradient as described by Meloni & Thompson (1996) .
Histological examination of gastrointestinal tract
Samples of duodenum, jejunum, ileum, caecum and terminal colon were taken from all the rats, either treated, untreated or control animals for histological examination. Villus length and crypt depth were measured in the ileum, jejunum and duodenum and recorded for all animals. For each anatomical location, 20 villi and 20 crypts were measured. The VC ratios were determined for uninfected untreated, infected untreated and infected treated animals. Statistical analysis was performed using hierarchical and nested analysis of variance (ANOVA) and a oneway factorial ANOVA with Scheffe! multiple range test (where P 0n05) using the program JUMP. Between-group differences and pooled differences were examined.
Pharmacokinetics using HPLC analysis
A total of sixteen 12-to 14-day-old Sprague-Dawley rats were dosed with a single oral dose of 100 mg\kg oryzalin. Groups of 4 rats were sacrificed 0n5, 1, 2 and 3 h following dosing, and the small intestine was removed and divided into 4 equal lengths. Each length of intestine was slit longitudinally and placed into 0n5 ml of PBS. Immediately following death the animal was exsanguinated by cardiac puncture using a heparinized syringe in order to obtain plasma drug concentrations. From each group of 4 animals, 1 animal was used for optimizing the HPLC method. Samples were then purified for HPLC analysis using Alltech solid-phase extraction columns according to the manufacturer's instructions.
High performance liquid chromatography (HPLC)
A Shimadzu HPLC system consisting of a communications bus module (CBM-10A), low pressure gradient valve (FCV-10AL), solvent delivery unit (LC-10AD), auto-injector (SIL-10A) and UV-VIS detector (SPD-10AD) connected to a chromatography work-station (CLASS-LC10) was used for HPLC. All chromatography was performed using a 150i3n9 mm Waters Symmetry C8 reverse phase column and detection of oryzalin was at a wavelength of 282 nm. The peak area was integrated. The mobile phase comprised 35 % acetonitrile, 30 % methanol and 35 % water (v\v) which was filtered through 0n45 µm filters. The oryzalin retention time was 4n8 min with a flow rate of 1n5 ml\min. Oryzalin in test plasma samples was quantified by area using a spiked plasma standard curve. This limit of detection was 20 ng\ml.
Sample preparation
The extraction procedure was a modification of the method of Dvorakova et al. (1997) . Plasma samples were initially extracted on C18 solid-phase extraction columns (200 mg extract-clean columns -Alltech). Each column was conditioned with 2 column volumes of methanol followed by 2 column volumes of water. Sample extraction was then performed with 0n5 ml of plasma sample and 1 ml of phosphate buffer (200 m, pH 7). The column was washed with 2 ml of 2 % acetonitrile and vacuum dried for 2 min prior to elution of the oryzalin with 2 ml of 100 % acetonitrile. Samples were then evaporated dry under nitrogen airflow at 35 mC. The residues were reconstituted with 200 µl of hexanes and 200 µl of mobile phase. The samples were then mixed vigorously for 30 sec and centrifuged at 2000 g for 2 min. A 50 µl aliquot of the lower phase was removed for HPLC analysis.
All HPLC results were analysed using regression analysis and slopes and elevation compared between segments.

Oocyst counts
Oocyst production was measured by counting the total number of oocysts in the processed gut of each rat. The oocysts recovered from the treated and untreated animals were counted on a haemocyto- Fig. 1 . Effect of oryzalin on the inhibition of oocyst excretion in mice dosed twice daily for 3 consecutive days (meanp..). Fig. 2 . Villus height and crypt depth were measured in the duodenum ($), jejunum ( ) and ileum () and VC ratios determined in uninfected rats (U), infected untreated rats (UI) and infected treated rats receiving the doses of oryzalin shown (mg\kg) on the horizontal axis. An asterisk (*) shows where the VC ratio was significantly different to that of the infected untreated animal. For multiple comparisons Scheffe! test significance was used where P 0n05.
meter and the results presented in Fig. 1 expressed as a percentage inhibition show a steady, almost linear dose-related reduction up to 25 mg\kg. The ED &! was determined to be 7 mg\kg. A maximum 88n5 % reduction was achieved at 25 mg\kg, and doses up to 200 mg\kg failed to achieve a higher inhibition of oocyst numbers.
Morphological differences between infected, uninfected, treated and untreated animals
Although treatment with oryzalin did not completely eliminate the infection, it was associated with a significant reduction in oocyst excretion and the pathological effects caused by the infection.
Histopathological effects associated with intestinal cryptosporidiosis included a significant decrease in VC ratio (Fig. 2) attributable to the combined effects of villus atrophy and crypt hyperplasia. There was also a mild increase in inflammatory cells and fibroplasia within the lamina propria of the small intestine. The caecal mucosa was attenuated and there was a decrease in the number of goblet cells. Lymphoid follicle development within the caecal mucosa was increased.
Similar changes were observed in infected rats treated with doses up to 6n25 mg\kg. At doses of 12n5 mg\kg or more there were minimal intestinal inflammatory changes. In the uninfected animals VC ratios were 4n3, 5n9 and 4n5 in the duodenum, jejunum and ileum respectively, whereas in the infected animals they were reduced to 2n3, 2n5 and 1n7 respectively (Fig. 2) . The oryzalin dosage at which the VC ratios were significantly different (P 0n05) to those of the untreated infected animals was 12n5 mg\kg or more in the duodenum, 50 mg\kg in the jejunum and 200 mg\kg in the ileum (Fig. 2) . A concomitant reduction in numbers of oocysts was noted with increasing dosage.
Numbers of Cryptosporidium stages observed histologically generally correlated with the degree of inflammation which was most severe in the caecum. Inflammatory changes in the caecum resolved once Cryptosporidium were no longer visible histologically. Generally the reduction in numbers of goblet cells associated with Cryptosporidium infection was reversed with doses of oryzalin of greater than 50 mg\kg, which corresponded with a reduction in Cryptosporidium numbers, although goblet cell numbers never returned to those seen in the uninfected controls.
Pharmacodynamic analysis
Analysis of the concentration of oryzalin in the small intestine showed that concentrations were higher in the more proximal segments of intestine (Fig. 3) The highest concentration (C max ) was found in the most proximal segment and this decreased further down the gut until the more distal segment has a C max that is half that of the more proximal segment. The time taken to peak concentration (T max ) was 30 min for all segments (Fig. 3) . The area under the curve (AUC) for each gut segment is shown in Fig. 4 . In terms of rate of disappearance of oryzalin from the gut contents, the AUC of the more proximal segment of intestine was 97 µg\ml\min, in the next segment the AUC was 20 % less than that found in the 1st and in the 3rd and 4th segments it was just 25 % and 10 % respectively of the AUC of the 1st segment. Regression analysis of the concentration of oryzalin in the gut at specific times revealed that no significant differences exist between segments in terms of their slope (P 0n1) but in terms of elevation or C max segments 1 and 2, while not significantly different from each other, were significantly different from the C max of segments 3 and 4 which were also not significantly different from one another (P 0n001). Plasma concentrations of oryzalin remained static from 30 min to 3 h post-dosing, although wide variation was noted between animals.

In the absence of a completely efficacious treatment for cryptosporidiosis, a coccidiostatic compound presents a real alternative to leaving the infection to progress unfettered. The dinitroaniline compounds have proved their anti-cryptosporidial effects in vitro (Arrowood et al. 1996 ; Armson et al. 1999 a, b) and in vivo (Armson et al. 1999 a, b) . The high inhibition achieved at low dosage in the current study (50 % inhibition at 7n5 mg\kg) suggests that the promising anti-cryptosporidial effects of oryzalin, and possibly other dinitroanilines, in vitro also occur in vivo, at least in rodents. The large variation of the oocyst numbers in the treated animals receiving lower doses of oryzalin is evident although the variation decreases as the doses increase. The variation was present in repeat experiments. Whether this heteroscedasticity is an attribute of the parasite or the host is unclear in the current study.
Reduction in the small intestinal VC ratio of infected untreated rats has also been reported previously in calves, although reduction was much greater in the current study. VC ratios in infected rats was less than half that of the uninfected rats, whereas the ratio in calves infected with the same parasite was almost 70 % that of uninfected calves (Ruest et al. 1997) . This may be a characteristic of the stage of development of the neonatal rats (7-8 days at time of infection) compared with the calves or it may be related to the severity of infection which is likely to alter between species.
The reduction in oocyst numbers as a result of oryzalin treatment in the current experiments corresponded with a decrease in intestinal inflammation and improvement in VC ratio. There was a mild persistence in the reduction of caecal goblet cells which may be attributable to persistence of low numbers of Cryptosporidium not detected by histological examination. Alternatively, the experimental time-scale may have been too short to achieve complete amelioration of the pathological effects.
The observed increase in crypt mitotic activity in infected animals is similar to that reported by Harp, Akili & Pesch (1999) in BALB\c neonatal mice infected with Cryptosporidium where the proliferation of cells in the crypt zone of infected mice was almost twice that of uninfected mice.
A dose-dependent decrease in oocyst numbers was seen with oryzalin at up to 30 mg\kg at which time the inhibition reached a plateau. While it is disappointing that higher doses failed to eradicate the infection completely, they did have an enormous impact on the severity of the infection in terms of oocyst numbers and gut pathology. This is best demonstrated by the dose-dependent increase in VC ratios, signifying the return of the gut towards the healthy state. Not surprisingly, the dose of oryzalin required to return the VC ratios to normal increased along the length of the small intestine where 5 mg\kg, 50 mg\kg and 200 mg\kg doses were required for a doubling of the VC ratios in the duodenum, jejunum and ileum respectively. The pharmacodynamic data demonstrated clearly that the more proximal segments receive the greater concentrations of the drug. For example, the AUC in the proximal segment of the small intestine is 10 times that of the most distal segment and the decrease along the 4 segments approximates a straight line. Thus the parasites in the more proximal gut are exposed to significantly greater concentrations of oryzalin for longer periods of time. This is exemplified by the reference to the MIC, IC *! and IC &! values shown in Fig. 3 . Moreover, the IC &! value determined in vitro, 750 n or 0n273 µg\ml, is maintained in the first 2 segments of the intestine for 2 h after dosing once with 100 mg\kg whereas this concentration is maintained for no more than 1 h in the 3rd segment and for just 30 min in the 4th segment. Thus, the concentration necessary to kill 50 % of the parasites is achieved and maintained in the first half of the gut but is maintained only transiently in the second half of the gut, resulting in persistence of the infection. Similarly the IC *! is achieved briefly in the 1st segment of the intestine only and the minimum lethal concentration (MLC) is not reached in any segment. Again the inability to achieve the MLC in the gut is reflected in the failure to eradicate the infection at high doses. It is noteworthy that the in vitro IC &! is achieved following a 48 h incubation of the drug. This finding is in complete agreement with the VC ratios and distribution of oocysts within the gut.
This study demonstrates that the in vitro activity of the dinitroaniline oryzalin also occurs in vivo and further optimization of the drug with regard to solubility and absorption is required. The oryzalin concentrations throughout the small intestine suggest that the barrier to successful treatment of cryptosporidiosis with oryzalin is delivery rather than poor activity.
Future studies will include chemical changes and optimization of this family of compounds as well as altered formulations in order to further decrease the rate of absorption. In addition, a detailed examination of the routes of excretion of the compound, similar to that performed with trifluralin (Erkog & Menzer, 1985) would be valuable in furthering our understanding of the disposition of this class of compounds.
